LianBio Stock Quote LIAN - Stock Price, News, Charts, Message Board, Trades

Register for streaming realtime charts, analysis tools, and prices.

Get Started

Home
Investing
Stocks
USA
NASDAQ
LianBio (LIAN) Quote

LianBio (LIAN)

0.319

0.00

( 0.00% )

Updated: 20:00:00

Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Current Price

0.319

Bid

0.3101

Ask

0.3449

Volume

-

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

Previous Close

0.319

Open

-

Last Trade

Last Trade Time

-

Financial Volume

-

VWAP

-

Average Volume (3m)

-

Shares Outstanding

-

Dividend Yield

-

PE Ratio

-

Earnings Per Share (EPS)

-

Revenue

-

Net Profit

-

LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically ... LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.lianbio.com

Headquarters

George Town, Cym

Founded

1970

LianBio is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LIAN. The last closing price for LianBio was $0.32. Over the last year, LianBio shares have traded in a share price range of $ 0.00 to $ 0.00.

LianBio currently has 0 shares outstanding.

Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities

LianBio Announces Voluntarily Delisting from Nasdaq

SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN) (“LianBio” or the “Company”), a biotechnology company dedicated to bringing innovative medicines to...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

LianBio Announces Completion of Strategic Review

SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN) (“LianBio” or the “Company”), a biotechnology company dedicated to bringing innovative medicines to...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Biotech Finds Success Following Holiday Weekend

If it’s not Artificial Intelligence (AI) related, the majority of headlines are typically talking about biotechs these days. That’s exactly what we came across this To read the full...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AREBAmerican Rebel Holdings Inc	$ 0.7151 (137.57%)	294.97M
NXLNexalin Technologies Inc	$ 2.14 (94.55%)	44.32M
SHCRSharecare Inc	$ 1.365 (76.27%)	35.78M
SPECSpectaire Holdings Inc	$ 0.543 (59.71%)	59.4M
MINMMinim Inc	$ 3.83 (33.92%)	42.04M
KAVLKaival Brands Innovations Group Inc	$ 1.475 (-48.61%)	3.35M
FLFVFeutune Light Acquisition Corporation	$ 5.01 (-40.57%)	43.63k
PBMPsyence Biomedical Ltd	$ 0.4039 (-32.68%)	2.28M
RELIReliance Global Group Inc	$ 0.464 (-23.17%)	7.65M
IVDAIveda Solutions Inc	$ 0.451 (-19.82%)	54.16k
NVDANVIDIA Corporation	$ 127.505 (-2.50%)	306.6M
AREBAmerican Rebel Holdings Inc	$ 0.7146 (137.41%)	294.98M
CRKNCrown Electrokinetics Corporation	$ 0.0408 (-18.40%)	139.12M
NKLANikola Corporation	$ 0.3753 (13.87%)	128.36M
ASTIAscent Solar Technologies Inc	$ 0.1114 (3.24%)	114.61M

Triple nickle

Triple nickle 3 months ago

Hmmm bunch of buy volume this morning

IVANj

IVANj 3 months ago

Looks like they gave it out cash divy at 4.8/share

Awl416

Awl416 3 months ago

ipo_dude

ipo_dude 8 months ago

Biggeoff

Biggeoff 8 months ago

Seems like a whale is loading. Every. Single. Dip. Has been bought up

MiamiGent

MiamiGent 8 months ago

Yes, it is trading under book, with a pipeline.
More tomorrow..

smokey1

smokey1 8 months ago

$ 5.60 p/s cash. They had $267 million at the end of June. They probably burned $17 for Q3 That leave $250 million at (9/30/23) Now another $350 from BMY.That's $600 million divided by 107 million shares =$5.60p/s.Is that correct?

MiamiGent

MiamiGent 8 months ago

LIAN While INM has been a meteor this morning, let's look under the hood of a smooth rising runner, LIANBIO

https://stockcharts.com/h-sc/ui?s=LIAN

$3.05 +1.6604 (+119.45%)
As of Oct-24-202310:51:20 AM ET

LIANBIO had news:

Why LianBio Stock Is Ripping Higher Today
BENZINGA

LianBio (NASDAQ:LIAN) shares are trading higher Tuesday after the company announced an agreement with Bristol Myers Squibb (NYSE:BMY) to purchase LianBio's exclusive rights to develop and commercialize mavacamten in mainland China, Hong Kong, Macau, Taiwan, Singapore and Thailand.

The Details:

Under the terms of the agreement, LianBio will receive a one-time payment of $350 million. The agreement also releases LianBio from payment obligations of up to $127.5 million in remaining milestone payments under the MyoKardia license agreement as MyoKardia, Inc. is now a wholly owned subsidiary of Bristol Myers Squibb.

"Over the past three years, we have worked in close collaboration with BMS to bring mavacamten to patients in Asia," said Yizhe Wang, Ph.D., CEO of LianBio. "The LianBio team executed a successful clinical development and regulatory strategy in our territories and has built robust launch infrastructure in anticipation of mavacamten's potential approval in China next year."

Shares of LIAN are up on heavy trading volume after the announcement. According to data from Benzinga Pro, more than 25.3 million shares have already been traded in the session, compared to the stock's 100-day average of 198 thousand shares.

So this solid news, a "real" play

LIAN has very substantial Institutional ownership, 75%

It had $279M in ready cash as of June 30th 10Q

Appears to have an annual burn of $82M but with a wire transfer of $350M coming, dilution is not likely.

Trading below book, even with today's run.

This could go on a while...

TheFinalCD

TheFinalCD 8 months ago

SOLD LAST 3.45 WHAT A GREAT TRADING STOCK

EVEN THOUGH HAD ME NERVOUS @ 2.13

TheFinalCD

TheFinalCD 8 months ago

$LIAN 2.13 WAS MY LOW BUY JUST SOLD 3.12

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173082745

Monksdream

Monksdream 8 months ago

ONE can always ask FINRA to blue sheet trades

TheFinalCD

TheFinalCD 8 months ago

THE WASH TRADING OUR GOV LETS HAPPEN IS UNREAL

TheFinalCD

TheFinalCD 8 months ago

$LIAN 2.40 Overall Risk Low https://dilutiontracker.com/app/search/LIAN

Monksdream

Monksdream 8 months ago

TheFinalCD

TheFinalCD 8 months ago

$LIAN NEWS Under the terms of the agreement, LianBio will receive a one-time payment of $350 million. In addition, LianBio will be released from payment obligations of up to $127.5 million in remaining milestone payments under the MyoKardia license agreement.

https://www.globenewswire.com/news-release/2023/10/24/2765435/0/en/LianBio-Enters-into-Agreement-with-Bristol-Myers-Squibb-for-Mavacamten-in-China-and-Other-Asian-Markets.html

Awl416

Awl416 8 months ago

LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets

Monksdream

Monksdream 9 months ago

Delayed Upgrade Clock